JPWO2020056371A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020056371A5
JPWO2020056371A5 JP2021514022A JP2021514022A JPWO2020056371A5 JP WO2020056371 A5 JPWO2020056371 A5 JP WO2020056371A5 JP 2021514022 A JP2021514022 A JP 2021514022A JP 2021514022 A JP2021514022 A JP 2021514022A JP WO2020056371 A5 JPWO2020056371 A5 JP WO2020056371A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
weight
salt
hyaluronic acid
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021514022A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500426A (ja
JP2022500426A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/051173 external-priority patent/WO2020056371A1/en
Publication of JP2022500426A publication Critical patent/JP2022500426A/ja
Publication of JPWO2020056371A5 publication Critical patent/JPWO2020056371A5/ja
Publication of JP2022500426A5 publication Critical patent/JP2022500426A5/ja
Priority to JP2024098708A priority Critical patent/JP2024137952A/ja
Pending legal-status Critical Current

Links

JP2021514022A 2018-09-13 2019-09-13 クロストリジウム毒素−ヒアルロン酸組成物 Pending JP2022500426A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024098708A JP2024137952A (ja) 2018-09-13 2024-06-19 クロストリジウム毒素-ヒアルロン酸組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862731063P 2018-09-13 2018-09-13
US62/731,063 2018-09-13
PCT/US2019/051173 WO2020056371A1 (en) 2018-09-13 2019-09-13 Clostridial toxin-hyaluronic acid compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024098708A Division JP2024137952A (ja) 2018-09-13 2024-06-19 クロストリジウム毒素-ヒアルロン酸組成物

Publications (3)

Publication Number Publication Date
JP2022500426A JP2022500426A (ja) 2022-01-04
JPWO2020056371A5 true JPWO2020056371A5 (https=) 2022-09-21
JP2022500426A5 JP2022500426A5 (https=) 2022-09-21

Family

ID=68069925

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021514022A Pending JP2022500426A (ja) 2018-09-13 2019-09-13 クロストリジウム毒素−ヒアルロン酸組成物
JP2024098708A Pending JP2024137952A (ja) 2018-09-13 2024-06-19 クロストリジウム毒素-ヒアルロン酸組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024098708A Pending JP2024137952A (ja) 2018-09-13 2024-06-19 クロストリジウム毒素-ヒアルロン酸組成物

Country Status (10)

Country Link
US (2) US20200108129A1 (https=)
EP (1) EP3849512A1 (https=)
JP (2) JP2022500426A (https=)
KR (2) KR20210057129A (https=)
CN (1) CN112888454A (https=)
AU (1) AU2019339519A1 (https=)
BR (1) BR112021004771A2 (https=)
CA (1) CA3112394A1 (https=)
MX (2) MX2021002992A (https=)
WO (1) WO2020056371A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
BR112019004935A2 (pt) 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada
CN115397399B (zh) * 2020-04-08 2025-06-27 玫帝托克斯股份有限公司 一种易于控制排出速度且稳定的肉毒杆菌毒素预填充式注射器剂型
US20240050538A1 (en) * 2020-12-18 2024-02-15 Atgc Co., Ltd. Pharmaceutical composition for long-term storage of liquid formulation of botulinum toxin
US20250295741A1 (en) 2022-11-07 2025-09-25 Allergan, Inc. Prevention of post-operative atrial fibrillation with a botulinum toxin
AU2023392523A1 (en) 2022-12-15 2025-04-10 Merz Pharma Gmbh & Co. Kgaa Injectable gel comprising botulinum toxin and uses thereof
WO2025151741A1 (en) * 2024-01-10 2025-07-17 Brown David Donaldson Methods of treating migraine headache or tension headache with hyaluronic acid

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636524A (en) 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US5099013A (en) 1985-03-12 1992-03-24 Biomatrix, Inc, Hylan preparation and method of recovery thereof from animal tissues
US4713448A (en) 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
US5143724A (en) 1990-07-09 1992-09-01 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US7758872B1 (en) 2003-02-07 2010-07-20 Eric Finzi Method of treating depression
WO2006096163A1 (en) 2005-03-03 2006-09-14 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
AU2016204034B2 (en) * 2005-10-06 2017-12-21 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
KR101604515B1 (ko) 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 a 활성 검정
KR20110106346A (ko) * 2008-12-10 2011-09-28 알러간, 인코포레이티드 클로스트리디움 독소 약제학적 조성물
MX2011009621A (es) 2009-03-13 2011-12-16 Allergan Inc Celulas utiles para ensayos de actividad del serotipo a de la toxina botulinica baados en inmunoensayos.
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
MX395130B (es) * 2016-03-02 2025-03-24 Merz Pharma Gmbh & Co Kgaa Composicion que comprende toxina botulinica
BR112019004935A2 (pt) * 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada

Similar Documents

Publication Publication Date Title
JP2022500426A5 (https=)
ES2638771T3 (es) Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol
TWI463978B (zh) Ophthalmic composition
JP5736635B2 (ja) ドライアイ治療剤
US9012503B2 (en) Ophthalmic composition
US20230355723A1 (en) Non-protein clostridial toxin compositions
ES2461617T3 (es) Composiciones farmacéuticas acuosas que contienen complejos borato-polioles
JP5244584B2 (ja) キサンタンガムおよびブドウ糖を含有する眼科用組成物
JP2025516814A (ja) 眼科用局所クリーム組成物および調製物における双性イオンの新規の適用方法
JPWO2020056371A5 (https=)
KR101858590B1 (ko) 안과용 조성물
JP3142842B1 (ja) 眼科用組成物及びソフトコンタクトレンズへの吸着抑制方法
KR102107471B1 (ko) 각결막 보호제 또는 각결막 장해 억제제
KR20150113156A (ko) 나트륨 히알루로네이트 및 카복시메틸셀룰로오스를 포함하는 인공 눈물
JP5800072B2 (ja) 眼科用組成物及び白濁・沈殿抑制方法
TWI501764B (zh) Ophthalmic compositions and methods for inhibiting turbidity and sedimentation
WO2017110874A1 (ja) 涙液油層安定化剤およびこれを含有する点眼剤
CN118284406A (zh) 稳定的包括肉毒杆菌毒素的液体制剂
KR102115285B1 (ko) 녹내장 치료용 점안 조성물
JP2001261578A (ja) 眼科用組成物
WO2018225729A1 (ja) ソフトコンタクトレンズ用眼科用組成物及びビタミンa分離抑制方法
RU2021109916A (ru) Композиции клостридиального токсина и гиалуроновой кислоты
JP2001158750A (ja) 眼科用組成物及び抗アレルギー薬の持続性向上方法
JP2017007995A (ja) 洗眼剤組成物及び洗眼方法
JPWO2020138135A1 (ja) 眼科用組成物